Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 5: CagriSema 1.0 mg versus tirzepatide 5 mg in type 2 diabetes on metformin and/or SGLT2 inhibitor
2023-509600-15-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 14
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) and obesity comparing CagriSema 1.0 mg/1.0 mg with Mounjaro 5 mg (2 arms). Primary endpoints: Change in HbA1c and Relative change in body weight. Started Aug 2024; status: completed.
02
Drugs
CagriSematirzepatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2023-509600-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509600-15-00.